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Elisabetta Rovida2, Monika Lewinska 3, Jesper B. Andersen 3, Christian Borgo 4, Mauro Salvi4, Daniele Ottaviani4,5,
Maria Ruzzene4 and Fabio Marra 1
Abstract
Cholangiocarcinoma (CCA) is a particularly aggressive hepatobiliary malignancy, for which the molecular mechanisms
underlying the malignant phenotype are still poorly understood, and novel and effective therapeutic strategies are
limited. The pro-survival protein kinase CK2 is frequently overexpressed in cancer and is receiving increasing interest as
an anti-tumor drug target. Its precise role in CCA biology is still largely unknown. Here we show that expression of the
CK2α and α’ catalytic subunits and of the β regulatory subunit is increased in human CCA samples. Increased
expression of CK2 subunits was shown in CCA cell lines compared to non-transformed cholangiocytes. We used
chemical inhibition of CK2 and genetic modiﬁcation by CRISPR/Cas9 to explore the contribution of CK2 to the
malignant phenotype of CCA cells. Disruption of CK2 activity results in cell death through apoptosis, reduced invasion
and migration potential, and G0/G1 cell cycle arrest. Importantly, CCA cells with a reduced CK2 activity are more
sensitive to chemotherapy. Altogether, our results demonstrate that CK2 signiﬁcantly contributes to increased
proliferative potential and augmented growth of CCA cells and indicate the rationale for its targeting as a promising
pharmacologic strategy for cholangiocarcinoma.
Introduction
Cholangiocarcinoma (CCA) is a lethal form of cancer
which accounts for approximately 10–25% of all hepato-
biliary malignancies1. Diagnosis in early stage of disease is
very difﬁcult due to lack of speciﬁc symptoms and bio-
markers and therefore, the prognosis is very poor2. Like
most cancers, development of CCA is a multistep process
characterized by genetic and epigenetic alterations in pivotal
genes leading to the activation of oncogenes and inactiva-
tion or loss of tumor suppressor genes3,4. Given the
aggressive nature of CCA and the absence of effective
therapeutic options, there is an unmet need for identiﬁca-
tion of novel therapeutic targets. However, despite
signiﬁcant advancement in the understanding of CCA
pathogenesis, little is known about the molecular mechan-
ism underlying the pro-tumorigenic properties of CCA cells.
CK2 is a constitutively active serine/threonine protein
kinase found in cells as a tetrameric enzyme, and is
composed of two catalytic subunits (α or its isoform α′)
and two regulatory subunits (β), the latter controlling
substrate-speciﬁcity and enzyme stability5. CK2 phos-
phorylates hundreds of substrates and is involved in many
cellular processes6. While it is ubiquitously expressed,
higher levels have been found in cancer cells as compared
to healthy cells7,8. Despite being ubiquitous, CK2 is dis-
pensable for normal cells9, while cancer cells rely on its
activity for their growth10. Indeed, CK2 inhibition was
proposed as an anticancer strategy11–15. Several CK2
inhibitors with cytotoxic properties in tumor cells and
anti-cancer effects in animal models have been devel-
oped16,17. The CK2 inhibitor, CX494518 has entered
clinical trials in phase I/II for different types of cancer,
© The Author(s) 2019
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Maria Ruzzene (maria.ruzzene@unipd.it)
Fabio Marra (fabio.marra@uniﬁ.it)
1Dipartimento di Medicina Sperimentale e Clinica and Center Denothe,
Università di Firenze, Florence, Italy
2Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università di
Firenze, Florence, Italy
Full list of author information is available at the end of the article.
Oncogenesis
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
including CCA where it is administered in combination
with cisplatin plus gemcitabine (NCT02128282). Recently,
the direct involvement of CK2 in CCA has been reported
in a study showing that CX4945 has an anti-proliferative
effect on CCA cells in vitro, and in mouse xenograft
models19. Moreover, a study in primary CCA cells
demonstrated a pro-apoptotic effect of CX4945 in cor-
relation with CK2 expression levels, and suggested the
potential beneﬁt of a combined CK2/TGF-β targeting20.
Here we provide a novel insight into the molecular
mechanisms by which CK2 contributes to the malignant
phenotype of CCA, exploiting pharmacologic and genetic
approaches.
Results
CK2 status in human CCA and CCA cell lines
To establish whether CK2 expression is higher in CCA,
we ﬁrst analyzed transcriptomic data from 104 surgically
resected CCA samples and matched surrounding livers.
Transcripts of CK2α, CK2α′ and CK2β subunits were
signiﬁcantly increased in tumor samples compared to
paired non-tumor liver tissue (Fig. 1a). Next, we examined
Fig. 1 Expression and activity of CK2 in cholangiocarcinoma samples and CCA cells lines. a Expression of CK2 catalytic (CSNK2A1 and
CSNK2A2) and regulatory (CSNK2B) subunits in human CCA tissues. CK2α, CK2α’ and CK2β mRNA expression were signiﬁcantly increased in tumor
lesions (T) (n= 104) compared to surrounding matched normal liver tissue (SL) (n= 60) using transcriptome data of CCA patients35. Statistical
signiﬁcance was determined by nonparametric Mann–Whitney test. Individual patient data are shown, and the thick horizontal line indicates the
mean of the values. §, P < 0.001 vs. T. b Relative quantitation of gene expression of CK2α, CK2α’ and CK2β in cholangiocytes, HUCCT-1 and CCLP-1
cells. *p < 0.05 versus cholangiocytes. (c) Twenty µg (left panel) or 40 µg (right panel) of proteins from total cell lysate were analyzed by Western blot
with the indicated antibodies. Tubulin was used as a loading control. d Activity of CK2 in cell lysates was measured using a CK2-speciﬁc peptide
substrate. *p < 0.05 versus cholangiocytes
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the expression of CK2 subunits in two CCA cell lines,
HUCCT-1 and CCLP-1 in comparison with non-
transformed cholangiocytes. Signiﬁcant overexpression of
CK2α, CK2α′ and β subunits was evident in CCA cells
compared to control cells, both at mRNA and protein
levels (Fig. 1b, c). To assess if CK2 overexpression corre-
lates with enhanced catalytic activity, we performed an
in vitro kinase assay of whole cell extracts using a CK2-
speciﬁc peptide as substrate (Fig. 1d). Consistently, CK2
activity was considerably higher in CCA cells than in non-
neoplastic biliary epithelial cells. Altogether, these ﬁndings
indicate that CK2 is elevated in CCA tissue and cells, thus
suggesting a potential role for CK2 in the biology of CCA.
Effect of the CK2 inhibitor CX4945 on CK2 activity and cell
viability in CCA cells
To explore the role of CK2 in CCA cell biology, we
treated cells with the CK2 inhibitor CX4945. To establish
whether CX4945 effectively blocks CK2 activity in CCA
cells, we measured CK2 enzymatic activity towards a
speciﬁc peptide substrate and evaluated the phosphor-
ylation state of the AktS129, a CK2 intracellular sub-
strate21. CK2 activity was reduced in a dose-dependent
manner by CX4945 in HUCCT-1 cells (Fig. 2a), and the
drop of CK2 kinase activity by CX4945 was conﬁrmed by
dephosphorylation of AktS129 (Fig. 2b). Similar results
were observed in CCLP-1 cells (data not shown).
Next, we assessed the effect of CK2 inhibition on CCA cell
viability by means of a MTT assay. CCA cells cultured in the
presence of increasing concentrations of CX4945 showed a
dose-dependent reduction in cell viability (Fig. 2c, d). These
results were conﬁrmed by treating cells with 4,5,6,7-Tetra-
bromobenzotriazole (TBB), a CK2 inhibitor structurally
unrelated to CX494522 (Supplementary Fig. 1), thus con-
ﬁrming the relevant role of CK2 in this context, even con-
sidering possible off-target effects of CX494523,24.
CK2 inhibition induces apoptosis in CCA cells
We investigated whether the reduction of CCA cell
viability in response to CX4945 was due to induction of
Fig. 2 Effects of the CK2 inhibitor CX4945 on CK2 activity and cell viability in CCA cells. a Cultured HUCCT-1 cells were treated with vehicle or
the indicated concentrations of CX4945 for 6 h. Activity of CK2 in cell lysates was measured towards the CK2-speciﬁc peptide substrate. *p < 0.05
versus vehicle. b Cultured HUCCT-1 cells were treated with vehicle or the indicated concentrations of CX4945 for 6 h. 25 µg of proteins from total cell
lysate were analyzed by western blot with the indicated antibodies. c, d CCA cells were treated with the indicated concentrations of CX4945 for 48 h.
MTT assay was performed at end of the treatment. *p < 0.05 versus control
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apoptosis. To this purpose, we pretreated CCA cells with
the pan-caspase inhibitor Z-VAD-fmk before adding the
CK2 inhibitor and ﬁnally measured cell viability. CX4945
treatment caused a reduction of cell viability of approxi-
mately 40% in CCA cell lines and this effect was partially
rescued by Z-VAD-fmk pretreatment, in a manner similar
to the one observed for the well-known pro-apoptotic
agent doxorubicin (Fig. 3a, b). This result suggests that
CK2 inhibition causes CCA cell death via a caspase-
dependent pathway. Consistently, the occurrence of
apoptosis in response to CX4945 was conﬁrmed by
appearance of the apoptotic PARP fragment in CCA
treated cells (Fig. 3c, d).
Because in other studies CX4945 was reported to induce
methuosis24,25, we checked whether this phenomenon
occurred under our experimental conditions. While we
conﬁrmed the appearance of large vacuoles in cells treated
with 50 µM CX4945, they were detected in less than 5% of
the cells at a concentration of 5 μM CX4945 (Supple-
mentary Fig. 2A), which is highly effective in inducing
CCA cell death (see Fig. 2).
CK2 inhibition reduces CCA cell migration and invasion
capabilities
To further explore the potential role of CK2 in the
modulation of the malignant phenotype of CCA cells, we
investigated the effects of CK2 inhibition on cell migration
and invasion using Boyden chamber assay (Fig. 4a, b).
CX4945 treatment reduced the ability to migrate in
response to fetal bovine serum, a potent chemotactic sti-
mulus, in both cell lines analyzed. Next, we examined the
effects of CX4945 on CCA cell invasion using matrigel-
coated inserts to simulate invasion through the extra-
cellular matrix. CK2 blockade markedly and signiﬁcantly
reduced the invasive behavior of CCA cells (Fig. 4c, d).
Interestingly CX4945 was able to affect migration and
invasion of CCA cells also in the absence of FBS stimula-
tion, indicating a relevant role of CK2 in the highly motile
and invasive phenotype of CCA cells even in unstimulated
conditions. The latter effect is in keeping with the con-
stitutive activation of CK2 observed in CCA cell lines.
The role of CK2 on CCA cell migration was further
assessed with the ‘wound healing’ assay, promoted by
FBS in the presence or absence of CX4945. The
experiment lasted for 6 h to minimize proliferation-
associated effects. As depicted in Fig. 4e, pharmacologic
inhibition of CK2 decreased the ability of CCA cells to
reduce wound width, conﬁrming the importance of CK2
in the modulation of migratory capabilities of CCA cells.
CK2 modulates proliferation and cell cycle progression in
CCA cells
We next examined the functional role of CK2 in the
control of proliferation of CCA cells. Upon CK2
Fig. 3 CK2 inhibition induces apoptosis of CCA cells. a CCA cells were incubated with doxorubicin (2 μg/ml) or CX4945 (5 μM) for 24 h, in the
presence or absence of the pan-caspase inhibitor, z-VAD-fmk (50 μM). MTT assay was performed at the end of the treatment. *p < 0.05 versus
Doxorubicin, **p < 0.05 versus CX4945. b CCA cells were treated with CX4945 5 µM for the indicated time points. Western blot analysis was
performed using the indicated antibodies
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inhibition, the time-dependent increase in the number of
CCA cells was signiﬁcantly reduced (Fig. 5a, b). To
examine the effect of CK2 inhibition on cell cycle reentry,
HUCCT-1 cells were serum starved and then stimulated
to reenter the cell cycle by the addition of FBS with or
without CX4945. In the presence of serum, about 60% of
the cell population entered the S or G2/M phase of the cell
cycle (Fig. 5c), while in presence of CX4945, the
Fig. 4 Effects of CK2 inhibition on HUCCT-1 and CCLP-1 motility and invasiveness. Cell migration (a, b) or invasiveness (c, d) were evaluated
using Boyden chamber assay with 10% FBS as chemotactic stimulus, in the presence or absence of 5 μM CX4945. Before the assay, CCA cells were
serum-starved for 24 h. *p < 0.05 vs untreated cells, **p < 0.05 vs. FBS-stimulated cells. eWound-healing assay. HUCCT-1 cells were plated at conﬂuency,
scratched with a pipette tip and allowed to heal the wound in 10% FBS-containing medium, in the presence or absence of CX4945 5 µM for 6 h.
Images were taken at the end of the experiment (original magniﬁcation ×200) and the wound area was quantiﬁed using Adobe Photoshop® software.
Scale bar corresponds to 200 µm. Data are expressed as the empty area (mean ± SEM) from three independent experiments. *p < 0.05 vs FBS
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proportion of cells in G0/G1 phase was comparable to
serum-deprived cells. In addition, CK2 inhibition was
associated with a decreased expression of cyclin E, a
protein essential for G1-to-S phase transition, and a
marked increase in the expression of the cyclin dependent
kinase inhibitor p27 (Fig. 5d), an important negative
modulator of G1 phase checkpoint.
To prove that CK2 inhibition is related to the above
described effects on the cell cycle, the experiments were
also performed in the presence of the unrelated inhibitor
TBB, which resulted in similar effects (Supplementary Fig.
3). In this case, a higher TBB concentration (80 µM) than
in cell viability assays was necessary, probably due to the
presence of a higher concentration of FBS (10%). Con-
sistently, a marked reduction of CK2 kinase activity was
only observed with 80 µM TBB, but not with 20 μM
(Supplementary Fig. 4A–B). Importantly, we did not
observe any vacuole formation in cells treated with 80 µM
TBB, excluding methuosis-like, off-target effects (Sup-
plementary Fig. 4C).
CK2α CCA knockout cells show reduced proliferation,
motility, and cell survival
To provide additional evidence that the effects observed
by the pharmacologic CK2 blockade were due to CK2
targeting, we knocked out the CK2α catalytic subunit,
Fig. 5 Effects of CK2 inhibition on CCA cell proliferation and cell cycle progression. a, b CCA cells were serum-starved for 24 h and then
stimulated with 10% FBS in the presence or absence of 10 μM CX4945 for 48 h. MTT assay was performed after starvation (0 h) or at the end of the
incubation period. *p < 0.05 vs. control. c Cultured HUCCT-1 were serum-starved for 24 h and then incubated with 10% FBS in the presence or
absence of 10 μM CX4945 for 24 h. Cell cycle phase distribution was determined by ﬂow cytometry. *p < 0.05 vs FBS. d Cultured HUCCT-1 were
serum-starved for 24 h and then incubated with 10% FBS in the presence or absence of 10 μM CX4945 for 24 h. Western blot analysis was performed
using the indicated antibodies
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exploiting the CRISPR/Cas9 genome editing technology.
With this technique, we generated a viable clone of
HUCCT-1 devoid of CK2α subunit (KO CK2α) (Fig. 6a).
Reduced CK2 catalytic activity was conﬁrmed by
decreased phosphorylation levels of the endogenous
substrate AktS129. We also observed a concomitant strong
reduction of the levels of the CK2β regulatory subunit.
This ﬁnding was not unexpected, since it has been already
Fig. 6 Effects of CK2α knockout on CCA cell biology. a Cellular lysates of wild type (WT) and a CK2α knockout clone (KO CK2α) were analyzed by
western blot with the indicated antibodies. b WT and KO CK2α cells were serum-starved for 24 h and incubated in the presence of 10% FBS for 24 h.
Proliferation rate was measured by bromodeoxyuridine (BrdU) incorporation assay. *p < 0.05 vs WT cells treated with FBS. Cell migration (c) or
invasiveness (d) in WT and KO CK2α cells were evaluated using a Boyden chamber assay, with FBS as chemotactic stimulus. Cells were serum-starved
for 24 h before the assay. *p < 0.05 vs control cells, **p < 0.05 vs FBS-stimulated cells. e, f Viability of WT and KO CK2α cells was assessed by MTT after
treatment with increasing concentrations of 5-ﬂuorouracil for 48 h or gemcitabine for 72 h. *p < 0.05 vs WT cells treated with the indicated drug at
the same concentration
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observed in previous studies and is probably due to a
rapid proteolytic degradation of CK2β in the absence of
the catalytic subunit26.
In CCA cells with this stable non-pharmacological CK2
reduction, we ﬁrst evaluated the effects on cell prolifera-
tion, measuring de novo DNA synthesis. As shown in Fig.
6b, exposure of HUCCT-1 WT cells to FBS for 48 h
caused a marked increase of DNA replication, whereas in
HUCCT-1 KO CK2α the stimulatory effect of FBS was
almost completely abrogated. In addition, KO CK2α cells
exhibited a strong reduction in FBS-induced migration
and invasion (Fig. 6c, d). Finally, considering the pro-
survival and antiapoptotic role of CK2, we checked the
sensitivity of KO CK2α cells to 5-ﬂuoracil and gemcita-
bine, two cytostatic drugs widely used for CCA treatment.
We found that deletion of CK2α signiﬁcantly enhanced
the cytotoxicity of both chemotherapeutics, conﬁrming a
prominent role of CK2 in mediating survival of CCA cells
(Fig. 6e, f).
Discussion
The identiﬁcation of effective treatments for CCA
requires a better knowledge of the molecular mechanisms
involved in growth and spread of cells isolated from this
type of cancer. The protein kinase CK2 is not an oncogene
per se, but it potentiates signaling pathways driven by
oncogenes, thus crucially contributing to the transformed
phenotype of malignant neoplasms. Indeed, many cancer
cells, at variance with normal ones, are addicted to CK2,
and rely on its activity for their survival, proliferation and
spreading10. In the present study, we provide evidence
that CK2 contributes to the malignant phenotype of CCA
cells via modulation of key cellular processes. In parti-
cular, we demonstrated that CK2 activity is essential for
survival, motility and cell cycle progression.
Evidence for the pivotal role of CK2 in the biology of
CCA cells was obtained using pharmacologic and genetic
approaches in two well-established cellular models
(HUCCT-1 and CCLP-1). These cells were shown to
overexpress all CK2 subunits and to possess increased
CK2 kinase activity compared to non-transformed cho-
langiocytes. Pharmacologic inhibition of kinase activity
with the well-characterized, clinical-grade CK2 inhibitor
CX4945 led to a reduction of CCA cell viability, an effect
attributable to activation of caspase-dependent apoptosis.
In addition, CK2 activity was implicated in the control of
local spread and metastatic potential of CCA cells, as
demonstrated by the reduction of the migratory and
invasive capacity of HUCCT-1 and CCLP-1 exposed to
CX4945. These results expand previous observations
demonstrating that CX4945 and the TGF-β inhibitor
LY2157299 have cooperative and complementary effects
on CCA survival and migration20. CK2 inhibition reduced
cell proliferation and blocked G1 to S phase progression.
Growth arrest was associated with increased expression of
p27 and reduction of cyclin E, two important regulators of
the G1-S transition, the expression of which is char-
acterized by an inverse relationship, in agreement with
our data. Modulation of p27 by CK2 has been reported in
other types of cancer cells27, whereas the connection
between CK2 and Cyclin E is a novel ﬁnding which
deﬁnes an additional regulatory role of CK2 during cell
cycle progression. Given the relevance of this pathway in
cancer biology, further studies are warranted to clarify the
molecular mechanisms linking CK2 with the CDK2/cyclin
E pathway.
Although CX4945 is considered quite selective28, other
CK2-independent functions have been ascribed to
CX4945, such as the suppression of phosphorylation of
serine/arginine (S/R) rich proteins with effects on alter-
native splicing of a wide range of genes23. Moreover,
CX4945 was found to induce methuosis, a non-apoptotic
form of cell death accompanied by the formation of large
ﬂuid-ﬁlled vacuoles, reported in both colon cancer25 and
CCA cells24. We checked the occurrence of methuosis in
CX4945-treated cells, but this was virtually not detected
at drug concentrations (5–10 µM) used in this study.
Since our treatment at 5 µM resulted in around 70% cell
death, the effects of CX4945 on CCA observed in this
study are unlikely to be due to methuosis. On the other
hand, the possibility that other forms of cell death con-
tribute to the effects of CX4945 cannot be completely
ruled out, as indicated by fact that a pan-caspase inhibitor
did not completely revert the actions of this drug on cell
viability.
To provide additional evidence that the observed effects
on CCA cells are due to CK2 inhibition, we conﬁrmed our
major ﬁndings using TBB, a CK2 inhibitor unrelated to
CX494522. Indeed, reduced cell viability and block of cell
cycle in the G0/G1 phase were also observed in cells
exposed to TBB. Moreover, we exploited the CRISPR/
Cas9 genome editing technology to generate viable CCA
cells devoid of the α catalytic subunit of CK2. Considering
that chemical targeting of CK2 by CX4945 is expected to
block both the α and α‘ isoform29,30, we tried to obtain a
double α/α′ knock-out in HUCCT-1 cells, but all attempts
were unsuccessful, since cells were not viable. This
negative result is per se interesting, since it conﬁrms the
‘addiction’ of CCA cells to CK2 for their survival. Indeed,
only non-transformed cells completely devoid of CK2
catalytic activity have been successfully generated so far26.
Nevertheless, despite using cells where only the α subunit
had been knocked down, a strong reduction of the
malignant features of CCA cells was observed. Speciﬁ-
cally, proliferation, migration, invasion, and survival when
exposed to cytostatic drugs were markedly and
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signiﬁcantly reduced in cells depleted of the CK2 α sub-
unit. Thus, complete abrogation of CK2 activity does not
appear to be necessary to negatively modulate the
aggressive phenotype of CCA cells. An alternative
hypothesis is that CK2 has isoform-speciﬁc functions for
the α subunit, not shared by α′, in determining the
aggressive properties of CCA. Although the α and α′
CK2 subunits are highly conserved in sequence and
usually considered overlapping in function, they have also
been reported to have speciﬁc roles31. Future work will be
necessary to conﬁrm or exclude this possibility, in the
context of CCA biology.
The results obtained in cultured CCA cells are markedly
strengthened by the analysis of transcriptome datasets from
surgically resected CCA specimens, which showed elevated
expression of CK2 catalytic and regulatory subunits in the
tumor in comparison to matched surrounding non-tumor
tissue. These data are in agreement with a previous study
that reported overexpression of the CK2α and CK2β genes
in several types of lethal cancers including hepatocellular
carcinoma32, and with data proposing a correlation
between overexpression of CK2β and CCA progression33.
In summary, our data strongly indicate that CK2 con-
tributes to the aggressive phenotype of CCA cells through
modulation of cell survival, cell cycle and cell motility, and
indicate that CCA cells with reduced CK2 activity are
more sensitive to conventional antitumor drugs. Of note,
most data were obtained using a pharmacologic inhibitor
that has been qualiﬁed for clinical trials. While our
investigation was performed at a molecular and cellular
level, another recent study has demonstrated that CX4945
is effective in reducing the growth of CCA cells in an
in vivo xenograft model in mice19, synergizing with con-
ventional drugs. Based on the results from our group and
from other scientists, CK2 targeting merits future eva-
luation as an additional approach to the treatment of
CCA, in combination therapies.
Materials and methods
Reagents
CK2α (C-terminal) antibodies were raised in rabbit34,
CK2α (N-terminal) (Cat N.: MCA3031Z) antibody was
from Biorad Laboratories (Hercules, CA, USA), CK2β
(Cat N.: ab76025) and p-Akt1 S129 (Cat N.: ab133458)
antibodies were from Abcam (Cambridge, UK). Cleaved
PARP (Cat N.: #9541) and p27Kip (Cat N.: #2552) anti-
bodies were from Cell Signaling Technology (Danvers,
MA, USA), Vinculin (Cat N.: V9131), α-Tubulin (Cat N.:
T5168) and Actin (Cat N.: A5441) were from Sigma-
Aldrich (St Louis MO, USA). Akt1 (Cat N.: sc-1618) and
Cyclin E (Cat N.: sc-481) antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Crispr/Cas9 all-in-
one plasmids were purchased from ATUMSM.CX4945
was from Glixx Laboratories (Hopkinton, MA, USA). TBB
was kindly provided by Dr. Z. Kazimierczuk, Warsaw,
Poland; Caspase inhibitor Z-VAD-FMK was from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Doxorubicin,
5-Fluoruracil (5-FU) and Gemcitabine were from Sigma-
Aldrich (St Louis MO, USA).
CCA patient database
The GSE26566 series matrix containing expression
values from Illumina humanRef-8 v2.0 expression bead-
chip arrays [transcript (gene) version] of 104 CCA
patients was downloaded from GEO35. Differences in
gene expression of speciﬁc genes of 104 tumor tissues (T)
versus 60 matched surrounding liver (SL) were evaluated.
All samples were obtained with approval by the institu-
tional review board of the National Institutes of Health
and collaborating institutions on the condition that
patients were anonymized.
Cell culture
CCA cell lines (HUCCT-1, CCLP-1) used in this study
were kindly provided by Dr. A.J. Demetris, University of
Pittsburgh and Dr. G. Alpini, Texas A&M Health Science
Center, USA. Cells were cultured according to conditions
described elsewhere36. The primary human intrahepatic
cholangiocyte cell line HiBEC (indicated as “cholangio-
cytes”) was from ScienCell. Experiments were performed
using cells between passages 2 and 8. All cell lines were
incubated at 37 °C in a humidiﬁed chamber supplemented
with 5% CO2. All cells used were negative for mycoplasma
(Mycoplasma detection kit, Roche, Germany).
Measurement of cell viability
Cell viability was detected by means of 3-(4,5-dimethyl-
thiazol-2-yl)-3,5-diphenyltetrazolium bromide (MTT)
reagent, a tetrazolium salt that is metabolized by mito-
chondrial dehydrogenases and produces a purple pre-
cipitate in viable cells. Cell suspension (1 × 104 to 2.5 × 104
cells in 100 μl) was incubated in each well of a 96-well plate
under different conditions, in the culture medium but with
1% (instead of 10%) FBS, where not differently indicated.
Then, 2 h before the end of the incubations, 10 μl of MTT
solution (5mg/ml in PBS) was added to each well. Incu-
bations were stopped by addition of 20 μl of lysis solution
at pH 4.7, consisting of 20% (w/v) SDS, 50% (v/v) N,N
dimethylformamide, 2%(v/v) acetic acid and 25Mm HCl.
Plates were read for absorbance at 570 nm, in a Multiskan
FC plate reader (Thermo Scientiﬁc, Waltham, MA, USA).
Analysis of cell cycle
Eighty thousands cells/well were seeded in multi-wells
dishes and exposed to the appropriate conditions. After
medium removal, 400 μl of solution containing 50 μg/ml
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propidium iodide, 0.1% w/v trisodium citrate, 0.1% NP40
was added. Samples were then incubated for 30min at 4 °C
in the dark and nuclei analyzed with a FACSCanto ﬂow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
BrdU incorporation assay
BrdU incorporation assay was performed using the
following colorimetric immunoassay: Cell Proliferation
ELISA, BrdU (colorimetric) Kit (Roche Applied Science,
Indianapolis, IN) based on the measurement of BrdU
incorporation. In total, 15,000 cells/well were seeded in
96-well plates, incubated in complete medium for 24 h
and serum-starved for additional 24 h. The assay was
performed following the manufacturer’s protocol.
Wound healing assay
HUCCT-1 cells (20,000 cells/well) were seeded in six-
well plates and allowed to form cell monolayer. Conﬂuent
CCA cells were serum starved for 16 h. After serum
starvation, a sterile 10 µl plastic pipette tip was used to
create a line-shaped wound across the cell monolayer, and
the detached cells were removed by rinsing with
phosphate-buffered saline (PBS). Next, cells were stimu-
lated with 10 % FBS in presence or absence of CX4945
5 µM for 6 h. Images were taken at the end of the
experiment (original magniﬁcation ×200) and the wound
area was quantiﬁed using Adobe Photoshop® software.
CRISPR/Cas9-mediated genome editing
CK2α knockout clone was generated by Crisp/Cas9-
mediated genome editing as described in Borgo et al.26.
All-in-one plasmids expressing Cas9-DasherGFP and
the sgRNA guide (pD1301-AD: CMV-Cas9-2A-GFP,
Cas9-ElecD) to target the speciﬁc CK2 subunit was
used. The sgRNA guide sequences are 5′- CCTGGA
TTATTGTCACAGCA-3′ (CK2α). Brieﬂy, HUCCT-1
cells were cultured in six-well dishes to 70–80% con-
ﬂuence. Cells were co-transfected with 1 μg of sgRNA
plasmid and Lipofectamine 3000 according to manu-
facturing instructions. Forty-eight hours post-transfec-
tion, cells were pelleted in PBS and sorted in 96-well
plates using ﬂuorescence-activated cell sorting (FACS)
with a FACSAria II cell sorter (BD BioSciences). Single
cells were expanded to obtain individual clones. Indi-
vidual clones were lysed and quantiﬁed as described
above. The absence of CK2α was veriﬁed by western
blotting.
CK2 activity assay in cell lysates
Proteins from cell lysates (1–2 μg) were incubated for
10min at 30 °C in 25 μl of a phosphorylation medium
containing 50 mM Tris–HCl (pH 7.5), 100mM NaCl,
10 mM MgCl2, 400 μM synthetic peptide-substrate
RRRADDSDDDDD and 50 μM [γ-33P] ATP (1000 cpm/
pmol). Assays were stopped by absorption onto phos-
phocellulose ﬁlters. Filters were washed four times in
75mM phosphoric acid and analyzed by a Scintillation
Counter (PerkinElmer).
RNA isolation and real time quantitative PCR
Total RNA from cells was isolated using the RNeasy kit
(QIAGEN Sciences, MD) according to the manufacturer’s
recommendations. The RNA concentration and quality
were measured using an optical Nanodrop
ND1000 spectrophotometer (Thermo Scientiﬁc). Total
RNA (1500 ng) was reverse transcribed into cDNA using
iScript Adv cDNA kit (Biorad) according to the manu-
facturer’s instructions. Changes in the mRNA expression
level of target genes were detected using SosAdvanced
Universal SYBR-Green SuperMix and the Corbett Rotor-
gene 6600 analyzer (Corbett Life Science, Sydney, Aus-
tralia). Relative gene expression was calculated as 2−ΔCt
(ΔCt=Ct of the target gene minus Ct of GAPDH).
We used the following pairs of primers to analyze the
gene expression:
CK2α forward 5′-TGTCCGAGTTGCTTCCCGATAC
TT-3′
CK2α reverse 5′-TTGCCAGCATACAACCCAAACT
CC-3′
CK2α’ forward 5′-AGCCCACCACCGTATATCAAAC
CT-3′
CK2α’ reverse 5′-ATGCTTTCTGGGTCGGGAAGA
AGT-3′
CK2β forward 5′-TTGGACCTGGAGCCTGATGAAG
AA-3′
CK2β reverse 5′-TAGCGGGCGTGGATCAATCCAT
AA-3′.
The real-time PCR results are normalized against the
control GAPDH housekeeping gene using the primers:
forward 5′-CAACGACCACTTTGTCAAGC-3′
reverse 5′-TCTTCCTCTTGTGCTCTTGC -3′
Western Blot analysis
Procedures for preparation of cell lysates, sodium
dodecyl sulfate polyacrylamide gel electrophoresis ana-
lysis and Western blotting have been described else-
where37. Quantiﬁcation of the signal was obtained by
chemiluminescence detection on a Image Quant
Las4000 (GE Healthcare Life Sciences) and subsequent
analysis with the ImageJ or Adobe Photoshop software.
Measurement of cell migration and invasion
Migration of HUCCT-1 or CCLP-1 cells was assayed
using modiﬁed Boyden chambers, Brieﬂy, 20,000 cells
were seeded in wells equipped with 8-μm pore ﬁlters
(Millipore Corp, MA, USA) and coated with rat tail col-
lagen (20 μg/ml) (Collaborative Biomedical Products,
Bedford, USA) or Matrigel (150 μg/ml) (BD Biosciences,
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MA, USA), to be used for chemotaxis and chemoinvasion
assays, respectively. After the time of incubation (16 h),
the migrated or invaded cells were ﬁxed, stained with
Giemsa, mounted counted at ×40 magniﬁcation. Data are
the average of cell counts obtained in 12 randomly chosen
high-power ﬁelds (HPF).
Statistical analysis
Autoluminograms and immunoﬂuorescence images are
representative of at least three experiments with com-
parable results. All barograms show the combined results
of three independent experiments, shown as mean ± SEM.
Unless speciﬁed otherwise, paired two-tailed Student’s t
test was applied to determine statistical signiﬁcance, for
normally distributed samples. P values lower than 0.05
were considered signiﬁcant.
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